Related Experiment Video
Updated: Jun 28, 2025
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
Efficacy of Sorafenib-Based Therapies for Non-Small Cell Lung Cancer
Morgann Hendrixson1, Yevgeniy Gladkiy1, Anita Thyagarajan2
1Boonshoft School of Medicine, Wright State University, Dayton, OH 45435, USA.
Abstract:
Lung cancer remains the leading cause of cancer-related deaths, with a poor prognosis. Of the two types, non-small cell lung cancer (NSCLC) is the major and most prevalent type and associated with low response rates to the current treatment options. Sorafenib, a multitargeted tyrosine kinase inhibitor used for various malignancies, gained attention for its potential efficacy in NSCLC. This review paper focuses on the findings of recent in vitro, in vivo, and clinical studies regarding the efficacy of sorafenib. Overall, sorafenib has shown definitive therapeutic potential in NSCLC cell lines, xenografts, and human subjects. Novel approaches to sorafenib delivery may improve its efficacy and should be the focus of further studies.
Insights
Sorafenib shows therapeutic promise for non-small cell lung cancer (NSCLC). Further research into novel drug delivery methods is recommended to enhance its effectiveness in treating this prevalent cancer.
Area of Science:
- Oncology
- Pharmacology
Background:
- Lung cancer is a leading cause of cancer mortality with poor prognosis.
- Non-small cell lung cancer (NSCLC) is the most common type, often showing limited response to existing therapies.
Purpose of the Study:
- To review recent evidence on the efficacy of sorafenib in non-small cell lung cancer.
- To assess the therapeutic potential of sorafenib based on in vitro, in vivo, and clinical data.
Main Methods:
- Literature review of in vitro studies.
- Analysis of in vivo (xenograft) studies.
- Evaluation of human clinical trial data.
Main Results:
- Sorafenib demonstrated significant therapeutic potential in NSCLC cell lines.
- In vivo studies confirmed sorafenib's efficacy in preclinical models.
- Clinical investigations indicated a positive therapeutic effect in human subjects.
Conclusions:
- Sorafenib exhibits definitive therapeutic potential for non-small cell lung cancer.
- Novel drug delivery strategies for sorafenib warrant further investigation to optimize efficacy.
More Related Videos
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...